表皮生长因子受体抑制剂诱发的皮肤黏膜反应20例临床分析

发布时间：2018-03-15 08:02

本文选题：表皮生长因子受体抑制剂　切入点：不良反应　出处：《临床皮肤科杂志》2014年06期 　论文类型：期刊论文

【摘要】：目的:探讨肿瘤靶向治疗药物表皮生长因子受体抑制剂(EGFRI)诱发皮肤黏膜反应的临床特征及治疗。方法:对20例应用EGFRI后发生皮肤黏膜反应的患者临床资料进行回顾性分析。结果:20例患者年龄48~78岁,痤疮样疹11例,脂溢性皮炎7例,毛发改变3例,口腔黏膜溃疡2例,甲沟炎2例;11例痤疮样疹中9例累及面颈部,2例累及下肢;7例脂溢性皮炎均位于头面部;皮疹严重程度分级轻度12例,中度7例,重度1例;轻度患者中9例自行缓解,3例通过局部治疗好转,中度患者中6例通过局部治疗好转,1例系统用药后好转;1例重度患者中断EGFRI治疗后好转。结论:EGFRI诱发的皮肤黏膜反应中,痤疮样疹占首位,其次为脂溢性皮炎,多数皮肤黏膜不良反应为轻、中度,经对症处理或停药后自行缓解。
[Abstract]:Objective: to investigate the clinical characteristics and treatment of epidermal growth factor receptor inhibitor (EGFRI) induced by tumor targeting therapy. Methods: the clinical data of 20 patients with skin and mucosal reaction after EGFRI were reviewed. Results 20 cases of 20 patients were 48 to 78 years old. 11 cases of acne like rash, 7 cases of seborrheic dermatitis, 3 cases of hair change, 2 cases of oral mucosal ulcer, 2 cases of thyroiditis and 11 cases of acne like rash, 9 cases involving face and neck, 2 cases involving seborrheic dermatitis of lower extremity, 7 cases of seborrheic dermatitis were all located on the head and face. The grade of severity of rash was mild in 12 cases, moderate in 7 cases, severe in 1 case, in which 9 cases of spontaneous remission were improved by local treatment. Among the moderate patients, 6 cases were improved by local therapy, 1 case was improved after systemic therapy and 1 case was improved after EGFRI treatment. Conclusion Acne rash is the most common type of skin and mucosal reaction induced by EGFRI, followed by seborrheic dermatitis. Most of the adverse reactions of skin and mucous membrane were mild and moderate.
【作者单位】：第二军医大学长海医院皮肤科;
【分类号】：R758.25

【共引文献】